Gastroösophageale Refluxkrankheit – was tun, wenn PPI nicht ausreichend wirksam,
                    verträglich oder erwünscht sind?

Joachim Labenz; Herbert Koop

doi:10.1055/s-0044-100740

Laryngo-Rhino-Otologie, Table of Contents

Laryngorhinootologie 2018; 97(03): 166-175
DOI: 10.1055/s-0044-100740

Übersicht

Gastroösophageale Refluxkrankheit – was tun, wenn PPI nicht ausreichend wirksam, verträglich oder erwünscht sind?

Gastro-Oesophageal Reflux Disease – How to Manage if PPI are not Sufficiently Effective, not Tolerated, or not Wished?

Joachim Labenz

,

Herbert Koop

Abstract

Zusammenfassung

Die Standardtherapie der GERD mit PPI ist weniger wirksam als gedacht: Mindestens 30 % der Patienten haben persistierende Symptome und Läsionen (Therapielücke). Bei persistierender Symptomatik oder Wunsch einer alternativen Behandlung ist eine stratifizierte Diagnostik erforderlich. Alginate und neue Operationsverfahren erweitern die Therapieoptionen

Schlüsselwörter

gastroösophageale Refluxkrankheit - Protonenpumpeninhibitor (PPI) - persistierende Symptome - nicht geheilte Ösophagitis - extraösophageale Manifestationen

Key words

gastrooesophageal reflux disease - proton pump inhibitor (PPI) - persisting symptoms - not healed oesophagitis - extraoesophageal manifestation

Full Text

References

Literatur
1 Labenz J, Labenz C. Prävalenz und natürlicher Verlauf der gastroösophagealen Refluxkrankheit. Gastroenterologe 2016; 11: 102-109
2 El-Serag HB, Sweet S, Winchester CC. et al. Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 2014; 63: 871-880
3 Vakil N, van Zanten SV, Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-1920
4 Koop H, Fuchs KH, Labenz J. et al. S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021–013. Z Gastroenterol 2014; 52: 1299-1346
5 Mössner J. The indications, applications, and risks of proton pump inhibitors – a review after 25 years. Dtsch Arztebl Int 2016; 113: 477-483
6 El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-737
7 Labenz J, Labenz G, Stephan D. et al. Unzureichende Symptomkontrolle unter Langzeittherapie mit PPI bei GERD – Fakt oder Fiktion?. MMW Fortschr Med 2016; 158 (Suppl. 04) 7-11
8 Boeckxstaens G, El-Serag HB, Smout AJPM. et al. Symptomatic reflux disease: the present, the past and the future. Gut 2014; 63: 1185-1193
9 Jackson MA, Goodrich JK, Maxan ME. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016; 65: 749-756
10 Fletscher J, Wirz A, Young J. et al. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121: 775-783
11 Mitchell DR, Derakhshan MH, Robertson EV. et al. The Role of the Acid Pocket in Gastroesophageal Reflux Disease. J Clin Gastroenterol 2016; 50: 111-119
12 Beaumont H, Bennink RJ, de Jong J. et al. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut 2010; 59: 441-451
13 Rohof WO, Bennink RJ, Smout AJ. et al. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11: 1585-1591
14 Woodland P, Batista-Lima F, Lee C. et al. Topical protection of human esophageal mucosal integrity. Am J Physiol Gastrointest Liver Physiol 2015; 308: G975-G980
15 Strugala V, Dettmar PW, Sarratt K. et al. A Randomized, controlled, crossover trial to investigate times to onset of the perception of soothing and cooling by over-the-counter heartburn treatments. J Int Med res 2010; 38: 449-457
16 Thomas E, Wade E, Crawford G. et al. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pockettargeting alginate-antacid (Gaviscon Double Action) – a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2014; 39: 595-602
17 Lai IR, Wu MS, Lin JT. Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy-negative reflux disease. World J Gastroenterol 2006; 12: 747-754
18 Pouchain D, Bigard MA, Liard F. et al. Gaviscon^® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. A direct comparative randomised trial. BMC Gastroenterol 2012; 23: 12-18
19 Lindow SW, Regnéll P, Sykes J. et al. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy. Int J Clin Pract 2003; 57: 175-179
20 George N, Abdallah J, Maradey-Romero C. et al. Review article: the current treatment of non-cardiac chest pain. Aliment Pharmacol Ther 2016; 43: 213-239
21 Ness-Jensen E, Lindam A, Lagergren J. et al. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol 2013; 108: 376-382
22 Schey R, Dickman R, Parthasarathy S. et al. Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease. Gastroenterology 2007; 133: 1787-1795
23 Manabe N, Haruma K, Ito M. et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus 2012; 25: 373-380
24 Reimer C, Lodrup AB, Smith G. et al. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016 DOI: 10.1111/apt.13567 [Epub ahead of print]
25 Weijenborg PW, de Schepper HS, Smout AJ. et al. Effects of antidepressants in patients with functional esophageal disorders or gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2015; 13: 251-259
26 Hunt RH, Yuan Y, Scarpignato C. Editorial: healing of refractory reflux oesophagitis–an ongoing unmet clinical need. Aliment Pharmacol Ther 2014; 40: 987-989
27 Labenz J. Facts and fantasies in extra-oesophageal symptoms in GORD. Best Pract Res Clin Gastroenterol 2010; 24: 893-904
28 Adcock JJ. TRPV1 receptors in sensitisation of cough and pain reflexes. Pulm Pharmacol Ther 2009; 22: 65-70
29 Morice AH. The cough hypersensitivity syndrome: A novel paradigm for understanding cough. Lung 2010; 188: S87-S90
30 Gibson PG, Vertigan AE. Management of chronic refractory cough. BMJ 2015; 351: h5590
31 Vertigan AE, Theodoros DG, Winkworth AL. et al. Chronic cough: a tutorial for speech-language pathologists. J Med Speech-Lang Pathol 2007; 15: 189-206
32 Desjardin M, Roman S, des Varannes SB. et al. Pharyngeal pH alone is not reliable for the detection of pharyngeal reflux events: A study with oesophageal and pharyngeal pH-impedance monitoring. United European Gastroenterology Journal 2014; 1: 438-444
33 Galmiche JP, Hatlebakk J, Attwood S. et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011; 305: 1969-1977
34 Ganz RA, Peters JH, Horgan S. et al. Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med 2013; 368: 719-727
35 Ganz RA, Edmundowicz SA, Taiganides PA. et al. Long-term outcomes of patients receiving a magnetic sphincter augmentation device for gastroesophageal reflux. Clin Gastroenterol Hepatol 2016; 14: 671-677
36 Banerjee R, Pratap N, Kalpala R. et al. Effect of electrical stimulation of the lower esophageal sphincter using endoscopically implanted temporary stimulation leads in patients with reflux disease. Surg Endosc 2014; 28: 1003-1009
37 Kapelle WF, Bredenoord AJ, Conchillo JM. et al. Electrical stimulation therapy of the lower oesophageal sphincter for refractory gastro-oesophageal reflux disease – interim results of an international multicentre trial. Aliment Pharmacol Ther 2015; 42: 614-625